S urrogate markers are a value tool in research and medicine, but they are not a substitute for clinical outcomes. Surrogate markers routinely used in clinical practice include low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and hemoglobin A1c (HbA1c). You should think of a surrogate marker as an intermediate endpoint; it may not be fully predictive of the drug's benefit or ability to modify disease complications in clinical practice.
Monitoring the changes in LDL-C and HDL-C concentration is useful in providing patient feedback on how lipid-lowering therapy is doing, but we need to remember that isolated changes in one parameter may not be fully predictive of changes in other body functions or cardiovascular risk. The proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are effective drugs for lowering LDL-C levels, but we do not know if they will change cardiovascular events (eg, stroke, myocardial infarction). In the past, we thought any reduction in LDL-C was beneficial, and it was assumed that any positive change in LDL-C level would be associated with a reduction in cardiovascular events. The same was true of any increase in HDL-C, but one clinical trial found an increase in the risk of death with torcetrapib (a drug designed to increase HDL-C levels). 1, 2 Because of concerns over the risk of unknown adverse effects with new drugs, I have noticed that some practitioners and health plans want to see larger and longer studies before widely using some new drugs.
The supportive information for some of the new drugs, vaccines, blood, and biologics products the US Food and Drug Administration (FDA) has been asked to approve can be classified as surrogate markers, yet these drugs cost from $1,000 to $100,000 and more per treatment or year. My quick review of the new drugs, vaccines, blood, and biologics that were approved in the United States in March, April, and May 2016 found that 27% appear to have used at least one surrogate marker for their primary endpoints.
Afstyla [antihemophilic factor (recombinant), single chain] was approved in May 2016 for the treatment of adults and children with hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding episodes; routine prophylaxis to reduce the frequency of bleeding episodes; and perioperative management of bleeding. 3 Afstyla was approved based on its ability to control bleeding episodes when used as an on-demand treatment, annualized bleeding rates when used as a prophylaxis regimen, and hemostasis similar to nonfactor deficiency patients during surgery. All of these appear to be the intended outcomes for this type of treatment and are not surrogate markers.
Cabometyx (cabozantinib) was approved in April 2016 for the treatment of patients with advanced renal cell carcinoma who have received prior antiangiogenic therapy. 4 Cabometyx was approved based on changes in progression-free survival, objective response rate, and overall survival compared to everolimus. The intended outcome for this type of treatment is decreased mortality and cure of the cancer.
Cinqair (reslizumab) was approved in March 2016 as add-on maintenance treatment of patients with severe asthma aged 18 years and older and with an eosinophilic phenotype. 5 Cinqair was approved based on frequency of exacerbations, changes in FEV1 (a surrogate marker), and changes in Asthma Control Questionnaire-7 and Asthma Quality of Life Questionnaire scores compared to placebo. The intended outcome for this type of treatment is decreased exacerbations, decreased emergency room visits and/or hospitalizations, and improved quality of life.
Descovy (emtricitabine/tenofovir alafenamide) was approved in April 2016 for combination therapy with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. 6 Descovy was approved based on viral suppression (a surrogate marker). The intended outcome for this type of treatment is viral suppression, restoration and preservation of immunologic function, reduction of HIV-associated Volume 51, September 2016 morbidity, increase in the duration and quality of survival, and prevention of HIV transmission. 7 Evomela (melphalan) was approved in March 2016 for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma and the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. 8 Evomela was approved based on disease response, successful myeloablation, and time to engraftment. The intended outcome for this type of treatment is myeloablation, engraftment, decrease mortality, and cure of the cancer.
Idelvion [Coagulation Factor IX (Recombinant), Albumin Fusion Protein] was approved in May 2016 for children and adults with hemophilia B (congenital Factor IX deficiency) for on-demand control and prevention of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes. 9 Idelvion was approved based on ability to control bleeding episodes when used as an on-demand treatment, annualized bleeding rates when used as a prophylaxis regimen, and hemostasis similar to non-factor deficiency patients during surgery. All of these can be classified as the intended outcome for this type of treatment and are not surrogate markers.
Inflectra (infliximab-dyyb) was approved in April 2016 as the biosimilar version of infliximab for the treatment of Crohn's disease, pediatric Crohn's disease, ulcerative colitis, rheumatoid arthritis in combination with methotrexate, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. 10 Some of the indications for Inflectra were based on surrogate markers.
Kovaltry [Antihemophilic Factor (Recombinant)] was approved in March 2016 for use in adults and children with hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. 11 Kovaltry was approved based on ability to control bleeding episodes when used as an on-demand treatment, annualized bleeding rates when used as a prophylaxis regimen, and hemostasis during surgery. All of these outcomes appear to be the intended outcome for this type of treatment and are not surrogate markers.
Nuplazid (pimavanserin) was approved in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. 12 Nuplazid was approved based on symptotic control and changes in scoring tools. The intended outcome for this type of treatment is improvement in the patient's condition and the scoring tools.
Ocaliva (obeticholic acid) was approved in May 2016 for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. 13 Ocaliva was approved based on changes in alkaline phosphatase and total bilirubin concentrations (both are surrogate markers). The intended outcome for this type of treatment is improvement in alkaline phosphatase and total bilirubin, but the ultimate endpoint is prevention of cirrhosis and cancer.
Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) was approved in March 2016 for the treatment of HIV-1 infection in patients 12 years of age and older as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies per mL or to replace a stable antiretroviral regimen in patients who are virologically suppressed (HIV-1 RNA <50 copies per mL) for at least 6 months with no history of treatment failure and no known substitutions associated with resistance of the individual components. 14 Odefsey was approved based on viral suppression and CD4+ cell counts (both are surrogate markers). The intended outcome for this type of treatment is viral suppression, restoration and preservation of immunologic function, reduction in HIV-associated morbidity, increase in the duration and quality of survival, and prevention of HIV transmission. 7 Taltz (ixekizumab) was approved in March 2016 for the treatment of treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 15 Taltz was approved based on changes in Psoriasis Area and Severity Index (PASI) and Physician Global Assessment scores and the amount of body surface area affected by the disease. The intended outcome for this type of treatment is achievement of PASI 75, PASI 90, and PASI 100 and reduction in the body surface area affected by the disease.
Tecentriq (atezolizumab) was approved in May 2016 for the patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or those with disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. 16 Tecentriq was approved based on objective response rate, reduction in tumor size, and duration of response. The intended outcome for this type of treatment is achievement of an objective response, reduction in tumor size, progression free survival, and cure of the cancer.
Venclexta (venetoclax) was approved in April 2016 for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion. 17 Venclexta was approved based on overall response rate, mean time to first response, duration of response, and change in tumor burden, which are also the intended outcomes for this type of treatment.
Zinbryta (daclizumab) was approved in May 2016 for the treatment of adult patients with relapsing forms of multiple sclerosis. 18 Zinbryta was approved based on annualized relapse rate, proportion of patients relapsed, proportion of patients who experienced confirmed disability progression, and the number of new or newly enlarging T2 hyperintense lesions, which are the intended outcomes for this type of treatment.
It is difficult to create an evidence-based formulary that is based on true clinical outcomes for some of these agents. Instead, the desired outcome data may not be available for several more years; but prescribers and patients want access to the drugs and biologics immediately and hope that the surrogate marker produces the intended outcome. The bigger issue concerns drugs classified as breakthrough therapy; these drugs must be used for the treatment of serious or life-threatening medical conditions and have preliminary clinical evidence associated with surrogate endpoints that indicates the drug or combination of drugs may demonstrate substantial improvement over existing therapies. However, what happens if they do not really make a difference after a few months or years of therapy? Should the pharmaceutical industry provide proof that their price is commensurate with the incremental health benefit delivered by their product? Should the pharmaceutical industry reimburse the patient or the health care system for a portion or the entire cost of the therapy? Will the government become involved in setting the price for new pharmaceuticals? Alternatively, should we continue to use prior authorization as one of the means to ration the access to these new products until the outcome evidence is available? No one system is perfect, and we will need to make changes as the price of some of these new specialty products escalates and the utilization rates increases.
